Gentamicin-loaded nanoparticles show improved antimicrobial effects towards Pseudomonas aeruginosa infection

• Main Authors: Abdelghany SM, Quinn DJ, Ingram RJ, Gilmore BF, Donnelly RF, Taggart CC, Scott CJ
• Format: Article
• Language: English
• Published: Dove Medical Press 2012-07-01
• Series: International Journal of Nanomedicine
• Online Access: http://www.dovepress.com/gentamicin-loaded-nanoparticles-show-improved-antimicrobial-effects-to-a10516
• ISSN: 1176-9114; 1178-2013

Sharif M Abdelghany,1,§ Derek J Quinn,2,§ Rebecca J Ingram,2 Brendan F Gilmore,1 Ryan F Donnelly,1 Clifford C Taggart,2 Christopher J Scott11School of Pharmacy, 2Centre for Infection and Immunity, Queen's University Belfast, UK §These authors contributed equally to this workAbstract: Gentamicin is an aminoglycoside antibiotic commonly used for treating Pseudomonas infections, but its use is limited by a relatively short half-life. In this investigation, developed a controlled-release gentamicin formulation using poly(lactide-co-glycolide) (PLGA) nanoparticles. We demonstrate that entrapment of the hydrophilic drug into a hydrophobic PLGA polymer can be improved by increasing the pH of the formulation, reducing the hydrophilicity of the drug and thus enhancing entrapment, achieving levels of up to 22.4 µg/mg PLGA. Under standard incubation conditions, these particles exhibited controlled release of gentamicin for up to 16 days. These particles were tested against both planktonic and biofilm cultures of P. aeruginosa PA01 in vitro, as well as in a 96-hour peritoneal murine infection model. In this model, the particles elicited significantly improved antimicrobial effects as determined by lower plasma and peritoneal lavage colony-forming units and corresponding reductions of the surrogate inflammatory indicators interleukin-6 and myeloperoxidase compared to free drug administration by 96 hours. These data highlight that the controlled release of gentamicin may be applicable for treating Pseudomonas infections.Keywords: anti-microbial, gentamicin, PLGA nanoparticles, Pseudomonas aeruginosa